Current Use of and Trends in Hematopoietic Cell Transplantation in the United States.
Activity
Hematopoietic cell transplantation
Summary slides
Journal
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Titre abrégé: Biol Blood Marrow Transplant
Pays: United States
ID NLM: 9600628
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
31
03
2020
revised:
06
04
2020
accepted:
07
04
2020
pubmed:
22
5
2020
medline:
24
6
2021
entrez:
22
5
2020
Statut:
ppublish
Résumé
Hematopoietic cell transplantation (HCT) is a well-established treatment to control and/or cure many malignant and nonmalignant diseases involving the hematopoietic system and some solid tumors. We report information about HCT procedures performed in the United States in 2018 and analyze trends and outcomes of HCT as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Overall, compared with 2017, the number of allogeneic HCTs performed in the United States increased by 1%, and the number of autologous HCTs decreased by 5%. Key findings are fewer autologous HCTs performed for non-Hodgkin lymphoma and increasing numbers of haploidentical HCTs, nearly all of which use post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. There is a continuing increase in HCT in adults age >70 years, particularly for acute myelogenous leukemia and myelodysplastic syndromes. Survival rates by disease, disease stage, donor type, and age are presented. This report, prepared annually by the CIBMTR, provides a snapshot of current transplant activity in the United States.
Identifiants
pubmed: 32438042
pii: S1083-8791(20)30225-1
doi: 10.1016/j.bbmt.2020.04.013
pmc: PMC7404814
mid: NIHMS1594414
pii:
doi:
Substances chimiques
Cyclophosphamide
8N3DW7272P
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e177-e182Subventions
Organisme : NIAID NIH HHS
ID : U01 AI126612
Pays : United States
Organisme : NHLBI NIH HHS
ID : R21 HL140314
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL141445
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA231141
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL128568
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL129472
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA111412
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA218285
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL131731
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL126589
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA152108
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States
Organisme : NHLBI NIH HHS
ID : U24 HL138660
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Informations de copyright
Copyright © 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
Références
Cancer. 2017 Aug 15;123(16):3141-3149
pubmed: 28472539
Blood. 2017 Aug 31;130(9):1156-1164
pubmed: 28674027
Biol Blood Marrow Transplant. 2019 Dec;25(12):2305-2321
pubmed: 31446199
Biol Blood Marrow Transplant. 2020 Jul;26(7):1247-1256
pubmed: 32165328